EA202192254A1 - Fcmr-связывающие молекулы и их применение - Google Patents
Fcmr-связывающие молекулы и их применениеInfo
- Publication number
- EA202192254A1 EA202192254A1 EA202192254A EA202192254A EA202192254A1 EA 202192254 A1 EA202192254 A1 EA 202192254A1 EA 202192254 A EA202192254 A EA 202192254A EA 202192254 A EA202192254 A EA 202192254A EA 202192254 A1 EA202192254 A1 EA 202192254A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fcmr
- application
- binding molecules
- antibodies
- pharmaceutical compositions
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962806237P | 2019-02-15 | 2019-02-15 | |
| PCT/CA2020/050195 WO2020163962A1 (en) | 2019-02-15 | 2020-02-14 | Fcmr-binding molecules and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA202192254A1 true EA202192254A1 (ru) | 2021-11-29 |
Family
ID=72043773
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA202192254A EA202192254A1 (ru) | 2019-02-15 | 2020-02-14 | Fcmr-связывающие молекулы и их применение |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US12286476B2 (enExample) |
| EP (1) | EP3924388A4 (enExample) |
| JP (1) | JP2022520817A (enExample) |
| KR (1) | KR20210139273A (enExample) |
| CN (1) | CN113993895A (enExample) |
| AU (1) | AU2020222408A1 (enExample) |
| BR (1) | BR112021016102A2 (enExample) |
| CA (1) | CA3130225A1 (enExample) |
| EA (1) | EA202192254A1 (enExample) |
| IL (1) | IL285585A (enExample) |
| MX (1) | MX2021009767A (enExample) |
| SG (1) | SG11202108837WA (enExample) |
| TW (1) | TWI857009B (enExample) |
| WO (1) | WO2020163962A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021009767A (es) | 2019-02-15 | 2021-11-17 | Univ Health Network | Moleculas de union de fmcr y usos de las mismas. |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP2221315A1 (en) | 2003-12-04 | 2010-08-25 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| JP6200437B2 (ja) | 2012-03-16 | 2017-09-20 | ユニバーシティ ヘルス ネットワーク | Ｔｏｓｏ活性を調節するための方法および組成物 |
| AU2014244444A1 (en) * | 2013-03-14 | 2015-09-24 | Amgen Inc. | CHRDL-1 antigen binding proteins and methods of treatment |
| AU2014286869A1 (en) * | 2013-07-03 | 2016-02-11 | University Health Network | Antibodies to Toso |
| US20150252434A1 (en) * | 2014-03-07 | 2015-09-10 | University Health Network | Methods and compositions for detection of targets involved in cancer metastasis |
| JP6877350B2 (ja) | 2014-11-05 | 2021-05-26 | ジェネンテック， インコーポレイテッド | 抗ｆｇｆｒ２／３抗体及びその使用方法 |
| EP3256163A4 (en) | 2015-02-11 | 2018-10-10 | University Health Network | Methods and compositions for modulating lilr proteins |
| EP3098237B1 (en) * | 2015-05-28 | 2018-08-01 | Universität Zu Köln | Anti-toso chimeric antigen receptor and its use |
| EP3559042A4 (en) | 2016-12-22 | 2020-11-25 | Icahn School of Medicine at Mount Sinai | ANTI-LILRB3 ANTIBODIES AND METHOD OF USING THEREOF |
| MX2021009767A (es) | 2019-02-15 | 2021-11-17 | Univ Health Network | Moleculas de union de fmcr y usos de las mismas. |
-
2020
- 2020-02-14 MX MX2021009767A patent/MX2021009767A/es unknown
- 2020-02-14 WO PCT/CA2020/050195 patent/WO2020163962A1/en not_active Ceased
- 2020-02-14 KR KR1020217029786A patent/KR20210139273A/ko active Pending
- 2020-02-14 EP EP20756467.5A patent/EP3924388A4/en active Pending
- 2020-02-14 CA CA3130225A patent/CA3130225A1/en active Pending
- 2020-02-14 US US17/430,311 patent/US12286476B2/en active Active
- 2020-02-14 AU AU2020222408A patent/AU2020222408A1/en active Pending
- 2020-02-14 CN CN202080025378.0A patent/CN113993895A/zh active Pending
- 2020-02-14 SG SG11202108837WA patent/SG11202108837WA/en unknown
- 2020-02-14 EA EA202192254A patent/EA202192254A1/ru unknown
- 2020-02-14 BR BR112021016102A patent/BR112021016102A2/pt unknown
- 2020-02-14 JP JP2021547401A patent/JP2022520817A/ja active Pending
- 2020-02-14 TW TW109104713A patent/TWI857009B/zh active
-
2021
- 2021-08-12 IL IL285585A patent/IL285585A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021009767A (es) | 2021-11-17 |
| CN113993895A (zh) | 2022-01-28 |
| EP3924388A4 (en) | 2023-02-15 |
| EP3924388A1 (en) | 2021-12-22 |
| TW202035461A (zh) | 2020-10-01 |
| SG11202108837WA (en) | 2021-09-29 |
| IL285585A (en) | 2021-09-30 |
| CA3130225A1 (en) | 2020-08-20 |
| JP2022520817A (ja) | 2022-04-01 |
| KR20210139273A (ko) | 2021-11-22 |
| TWI857009B (zh) | 2024-10-01 |
| US12286476B2 (en) | 2025-04-29 |
| WO2020163962A1 (en) | 2020-08-20 |
| BR112021016102A2 (pt) | 2021-11-09 |
| AU2020222408A1 (en) | 2021-09-09 |
| US20220089725A1 (en) | 2022-03-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20210154B1 (ar) | مثبطات kif18a | |
| EA202092907A1 (ru) | Мультиспецифические связывающие белки и их усовершенствования | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| EA201890145A1 (ru) | Антитела к фактору xi и способы их применения | |
| EA202290054A1 (ru) | Полиспецифические антитела, содержащие только тяжелые цепи, которые связываются с cd22 и cd3 | |
| EA202092086A1 (ru) | Ингибиторы аргиназы | |
| EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
| BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
| EA201992350A1 (ru) | Комбинированные лекарственные средства, нацеленные на pd-1, tim-3 и lag-3 | |
| EA202090401A1 (ru) | Анти-tim-3 антитела и их применение | |
| EA202090387A1 (ru) | Белки, связывающие nkg2d, cd16 и flt3 | |
| EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
| EA202090372A1 (ru) | Универсальные соединения авт и их применение | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| MX2022005775A (es) | Compuestos terapeuticos y metodos de uso. | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
| EA201892225A1 (ru) | АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ | |
| EA202092518A1 (ru) | Композиции и способы лечения рака | |
| EA202090014A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202191476A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202192488A1 (ru) | Антитела против tsg-6 и их применения | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202190807A1 (ru) | Антитела к синуклеину | |
| EA202191058A1 (ru) | Антитела против муцина-16 и способы их применения |